ARCHIVES

CMS Considering Regulatory Standards for Drug Company Bundling of Products.

This article is from The Cancer Letter archive.

Vol. 32 No. 37 | October 20, 2006

Download PDF Visit The Full Archive

Related Articles

DCCP Board Okays Concept Of Study On Black/White Survival Differences

March 5, 1982

Acupuncture Can Relieve Side Effects of Hormone Treatment

April 29, 2011

Five Proposals Submitted In Recompetition Of FCRF Operations/Support Contract; Now Under Review

January 2, 1987

FDA Discloses Responses, Toxicities For Burzynski’s “Antineoplastons”

April 24, 1998

In Brief: House Money Bill Reportedly Will Not Increase

September 18, 1981

NIH institute directors, in response to question from Sen. Arlen Specter, say Bush Administration’s stem cell research policy is harmful to NIH leadership in science.

April 8, 2005